Oxford, UK - 13 December 2007:Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that it has initiated a Phase I/II trial of ProSavin, its novel gene-based treatment for Parkinson’s disease. This follows regulatory clearance from the French Health Products Safety Agency (AFSSAPS) of the Company’s Clinical Trial Application. Patient recruitment for the Phase I/II trial will start immediately. The trial is being conducted at the Henri Mondor Hospital in Créteil, which is a European centre of excellence for neurosurgery and a member of the Assistance Publique Hôpitaux de Paris (APHP) in France.
